Company Focus
Baxter
Latest Baxter News
Pharmaceutical
Russia has faced with the shortage of oncology drug Uromitexan (mercapto ethane sulphonacid; mesna), for which last deliveries to the country were in the spring of 2023, reports The Pharma Letter’s local correspondent. 15 May 2024
Related News
Insights
Company Spotlight
A Canadian biotech company focussed on utilising lipid nanoparticle (LNP) for nucleic acid delivery.
Latest News & Features of interest to Baxter
Biotechnology
Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx. 19 December 2024
Biotechnology
December 19, 2024
The US Food and Drug Administration (FDA) approved Ryoncil (remestemcel-L-rknd), from Australia’s Mesoblast, whose shares rocketed 54% to A$3.05 on the news. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
US healthcare giant Johnson & Johnson has announced the submission of a Type II variation application to the European Medicines Agency (EMA). 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Pharmaceutical
ENA Respiratory, an Australian pharma developing innate immune modulators to prevent complications associated with respiratory viral infections in at-risk populations, has announced the publication of results of its Phase IIa study with its liquid formulation of INNA-051 in ERJ Open Research. 18 December 2024
Pharmaceutical
In significant efforts to strengthen public health and improve vaccine access in Africa, the US International Development Finance Corporation, the African Development Bank and the International Finance Corporation (IFC) have jointly announced a $45 million financing package for VaxSen, a subsidiary of Senegal’s Institut Pasteur de Dakar (IPD). 18 December 2024
Biotechnology
China's drug regulator has approved clinical trials for an experimental mpox vaccine developed by Sinopharm, marking a significant step in the country’s efforts to offer an alternative jab. 17 December 2024
Biotechnology
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has licensed an indication extension to Blincyto (blinatumomab) to treat adults with Philadelphia chromosome negative CD19-positive B-cell precursor acute lymphoblastic leukaemia (B-ALL) in the consolidation phase. 17 December 2024
Latest In Brief for Baxter
Biotechnology
Colorado, USA-based OncoVerity announced the closing of a series A extension led by existing investors, argenX and RefinedScience. The value was not disclosed, but this extension follows a $30 million Series A fundraiser in March 2023. 22 November 2024
Latest Relevant Ones To Watch News
Privately-held Certa Therapeutics, a biotech developing precision therapies for fibrotic diseases, has acquired fellow Australian firm OccuRx. 19 December 2024
16 December 2024
3 December 2024
28 November 2024
26 November 2024
19 November 2024
5 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze